Pfizer Raises EPS Guidance and Expands Cost-Cutting Plan While Boosting Dividend Appeal

Group 1 - Pfizer Inc. reported a year-over-year revenue increase of 10% in Q2 2025, reaching $14.7 billion, driven by strong demand for the Vyndaqel family of drugs [2][3] - The company raised its full-year 2025 adjusted diluted EPS guidance by $0.10 to a range of $2.90 to $3.10 [3] - Pfizer expanded its cost-cutting plan, aiming for an additional $1.7 billion in savings through 2027, raising the total savings goal to $7.7 billion, with approximately $4.5 billion expected to be realized by the end of 2025 [3] Group 2 - Pfizer is recognized as one of the best Fortune 500 dividend stocks, offering an attractive dividend yield of 7.20% [4] - The company, founded in 1849, focuses on developing and manufacturing a wide range of medicines and vaccines across various therapeutic areas, including oncology, cardiology, and immunology [4]